Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 22 | 2013 | 757 | 2.240 |
Why?
|
| Hypolipidemic Agents | 14 | 2009 | 190 | 1.670 |
Why?
|
| Dyslipidemias | 7 | 2010 | 245 | 1.520 |
Why?
|
| Anticholesteremic Agents | 14 | 2009 | 245 | 1.500 |
Why?
|
| Coronary Artery Disease | 13 | 2014 | 894 | 1.390 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 79 | 1.150 |
Why?
|
| Lipoproteins, HDL | 4 | 2012 | 118 | 1.100 |
Why?
|
| Atherosclerosis | 6 | 2012 | 1002 | 1.080 |
Why?
|
| Pyrroles | 5 | 2013 | 187 | 1.030 |
Why?
|
| Simvastatin | 6 | 2009 | 77 | 1.020 |
Why?
|
| Coronary Disease | 10 | 2007 | 721 | 1.000 |
Why?
|
| Azetidines | 4 | 2009 | 64 | 0.920 |
Why?
|
| Hyperlipidemias | 7 | 2005 | 198 | 0.910 |
Why?
|
| Cholesterol, HDL | 8 | 2012 | 395 | 0.820 |
Why?
|
| Clinical Trials as Topic | 14 | 2008 | 1157 | 0.810 |
Why?
|
| Cholesterol, LDL | 15 | 2006 | 604 | 0.780 |
Why?
|
| Pravastatin | 5 | 2008 | 22 | 0.600 |
Why?
|
| Myocardial Infarction | 7 | 2008 | 1102 | 0.500 |
Why?
|
| Hypercholesterolemia | 6 | 2005 | 236 | 0.480 |
Why?
|
| Coronary Artery Bypass | 5 | 2014 | 537 | 0.470 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2014 | 184 | 0.460 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2007 | 703 | 0.430 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 70 | 0.420 |
Why?
|
| Hypolipoproteinemias | 1 | 2013 | 4 | 0.420 |
Why?
|
| Musculoskeletal Pain | 1 | 2013 | 16 | 0.410 |
Why?
|
| Diabetes Complications | 1 | 2014 | 206 | 0.400 |
Why?
|
| Muscle, Skeletal | 2 | 2013 | 1046 | 0.390 |
Why?
|
| Cardiovascular Diseases | 4 | 2007 | 2090 | 0.390 |
Why?
|
| Oxidative Stress | 4 | 2012 | 876 | 0.390 |
Why?
|
| Rhabdomyolysis | 2 | 2003 | 37 | 0.380 |
Why?
|
| Cholesterol | 5 | 2004 | 574 | 0.380 |
Why?
|
| Niacin | 3 | 2009 | 59 | 0.360 |
Why?
|
| Arteriosclerosis | 3 | 2002 | 149 | 0.360 |
Why?
|
| Myocardial Ischemia | 5 | 2002 | 365 | 0.350 |
Why?
|
| Heart Failure | 7 | 2009 | 2428 | 0.350 |
Why?
|
| Inflammation | 5 | 2007 | 1593 | 0.350 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2009 | 110 | 0.340 |
Why?
|
| Hypertension | 4 | 2010 | 1396 | 0.330 |
Why?
|
| Renin-Angiotensin System | 2 | 2001 | 104 | 0.330 |
Why?
|
| Humans | 66 | 2014 | 134064 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2002 | 226 | 0.310 |
Why?
|
| Lipids | 3 | 2009 | 566 | 0.290 |
Why?
|
| Lipoproteins, LDL | 2 | 2006 | 137 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2008 | 1217 | 0.280 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 937 | 0.270 |
Why?
|
| Ezetimibe | 4 | 2009 | 98 | 0.260 |
Why?
|
| Risk Factors | 13 | 2010 | 11164 | 0.260 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 259 | 0.250 |
Why?
|
| Sympathetic Nervous System | 1 | 2005 | 67 | 0.240 |
Why?
|
| Angina, Unstable | 2 | 2005 | 55 | 0.240 |
Why?
|
| Tyrosine | 2 | 2002 | 161 | 0.230 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 360 | 0.230 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 518 | 0.230 |
Why?
|
| Drug Therapy, Combination | 6 | 2009 | 1199 | 0.230 |
Why?
|
| Allylamine | 1 | 2004 | 8 | 0.220 |
Why?
|
| Homeostasis | 1 | 2008 | 751 | 0.210 |
Why?
|
| Pyridines | 2 | 2003 | 250 | 0.210 |
Why?
|
| Intestinal Absorption | 1 | 2004 | 193 | 0.210 |
Why?
|
| Insulin | 1 | 2008 | 1260 | 0.200 |
Why?
|
| Energy Metabolism | 1 | 2008 | 814 | 0.200 |
Why?
|
| Endothelium, Vascular | 4 | 2010 | 522 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 129 | 0.190 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 65 | 0.190 |
Why?
|
| Liver | 3 | 2008 | 1880 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 365 | 0.170 |
Why?
|
| Biological Transport | 2 | 2012 | 371 | 0.170 |
Why?
|
| Myositis | 1 | 2001 | 104 | 0.170 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2000 | 29 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2008 | 1416 | 0.170 |
Why?
|
| Prognosis | 4 | 2012 | 5084 | 0.160 |
Why?
|
| Obesity | 2 | 2008 | 2446 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2000 | 286 | 0.150 |
Why?
|
| Lipoproteins, VLDL | 2 | 2009 | 57 | 0.150 |
Why?
|
| Neoplasms | 1 | 2013 | 3035 | 0.140 |
Why?
|
| Survival Rate | 4 | 2006 | 2218 | 0.140 |
Why?
|
| Stroke | 2 | 2003 | 1075 | 0.140 |
Why?
|
| Triglycerides | 5 | 2007 | 617 | 0.130 |
Why?
|
| Disease Progression | 5 | 2010 | 2264 | 0.130 |
Why?
|
| Male | 24 | 2014 | 66047 | 0.120 |
Why?
|
| Endocarditis | 1 | 1997 | 106 | 0.120 |
Why?
|
| Blood Coagulation | 2 | 2011 | 134 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2008 | 4933 | 0.120 |
Why?
|
| Lipoproteins | 3 | 2009 | 192 | 0.120 |
Why?
|
| Female | 21 | 2014 | 71846 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2013 | 6602 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 293 | 0.100 |
Why?
|
| Coronary Circulation | 2 | 2008 | 220 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 3 | 1999 | 50 | 0.100 |
Why?
|
| Lovastatin | 1 | 1992 | 23 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 169 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2005 | 252 | 0.100 |
Why?
|
| Insulin Resistance | 2 | 2008 | 700 | 0.100 |
Why?
|
| Drug Interactions | 3 | 2000 | 261 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2012 | 3729 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2002 | 79 | 0.090 |
Why?
|
| Double-Blind Method | 5 | 2009 | 1664 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2006 | 13049 | 0.090 |
Why?
|
| Indoles | 3 | 1999 | 203 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2170 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 469 | 0.090 |
Why?
|
| Heart Transplantation | 3 | 2005 | 895 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2005 | 471 | 0.090 |
Why?
|
| Vasoconstriction | 1 | 2010 | 103 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 3487 | 0.080 |
Why?
|
| Lipoproteins, IDL | 1 | 2009 | 6 | 0.080 |
Why?
|
| Myocardium | 3 | 2005 | 1046 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 378 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 824 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 459 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 52 | 0.070 |
Why?
|
| Coronary Occlusion | 1 | 2008 | 29 | 0.070 |
Why?
|
| Cholestyramine Resin | 3 | 1996 | 13 | 0.070 |
Why?
|
| Resistin | 1 | 2007 | 31 | 0.070 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 50 | 0.070 |
Why?
|
| Adiponectin | 1 | 2007 | 129 | 0.070 |
Why?
|
| Gemfibrozil | 2 | 1996 | 4 | 0.070 |
Why?
|
| Biomarkers | 3 | 2005 | 3432 | 0.070 |
Why?
|
| Middle Aged | 16 | 2013 | 29399 | 0.060 |
Why?
|
| Colestipol | 2 | 1996 | 6 | 0.060 |
Why?
|
| Parasympathetic Nervous System | 1 | 2005 | 15 | 0.060 |
Why?
|
| Leptin | 1 | 2007 | 224 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2005 | 89 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 239 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1420 | 0.060 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2004 | 5 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 388 | 0.050 |
Why?
|
| Greece | 1 | 2003 | 11 | 0.050 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2002 | 3 | 0.050 |
Why?
|
| Animals | 5 | 2008 | 36539 | 0.050 |
Why?
|
| Collagen | 2 | 2001 | 330 | 0.050 |
Why?
|
| Platelet Function Tests | 1 | 2002 | 41 | 0.050 |
Why?
|
| Time | 1 | 2002 | 101 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 242 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1741 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 149 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2002 | 35 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2002 | 174 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2002 | 148 | 0.050 |
Why?
|
| Homocysteine | 1 | 2002 | 120 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 1997 | 609 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2001 | 138 | 0.040 |
Why?
|
| Cardiac Catheterization | 2 | 2002 | 667 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 285 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 1999 | 35 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 391 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1340 | 0.040 |
Why?
|
| Isosorbide Dinitrate | 1 | 1998 | 4 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 14 | 0.040 |
Why?
|
| Metoprolol | 1 | 1998 | 22 | 0.040 |
Why?
|
| Xylenes | 1 | 1998 | 13 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 42 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 24 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 146 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 228 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 20 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 806 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 1998 | 49 | 0.040 |
Why?
|
| Aged | 8 | 2013 | 21753 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 703 | 0.040 |
Why?
|
| Cocaine | 1 | 1999 | 208 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1998 | 71 | 0.040 |
Why?
|
| Fistula | 1 | 1998 | 53 | 0.040 |
Why?
|
| United States | 2 | 2004 | 11748 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 208 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1998 | 63 | 0.030 |
Why?
|
| Prevalence | 1 | 2004 | 2684 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 214 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 56 | 0.030 |
Why?
|
| Clofibrate | 1 | 1996 | 1 | 0.030 |
Why?
|
| Adult | 11 | 2000 | 31961 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1997 | 43 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1997 | 198 | 0.030 |
Why?
|
| Fenofibrate | 1 | 1996 | 61 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1997 | 148 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2000 | 708 | 0.030 |
Why?
|
| Morbidity | 1 | 1997 | 256 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 3227 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 563 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2002 | 5476 | 0.030 |
Why?
|
| Probucol | 1 | 1994 | 1 | 0.030 |
Why?
|
| Clofibric Acid | 1 | 1994 | 3 | 0.030 |
Why?
|
| Fibric Acids | 1 | 1994 | 7 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1996 | 136 | 0.030 |
Why?
|
| Incidence | 1 | 2002 | 3414 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1998 | 460 | 0.030 |
Why?
|
| Time Factors | 6 | 2005 | 6604 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 897 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 1998 | 573 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1997 | 567 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 5206 | 0.020 |
Why?
|
| Etanercept | 2 | 2002 | 47 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2000 | 1094 | 0.020 |
Why?
|
| Coronary Angiography | 3 | 1999 | 485 | 0.020 |
Why?
|
| Echocardiography | 1 | 1997 | 1131 | 0.020 |
Why?
|
| Acyl Coenzyme A | 1 | 1991 | 25 | 0.020 |
Why?
|
| Naphthalenes | 1 | 1991 | 37 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 6304 | 0.020 |
Why?
|
| Age Factors | 1 | 1997 | 2997 | 0.020 |
Why?
|
| Adolescent | 2 | 2005 | 20600 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1909 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 1163 | 0.020 |
Why?
|
| Cardiovascular Agents | 2 | 1998 | 90 | 0.020 |
Why?
|
| Adenosine | 2 | 1998 | 140 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 1310 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 2573 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2005 | 105 | 0.010 |
Why?
|
| HIV Infections | 1 | 1997 | 2074 | 0.010 |
Why?
|
| Mice | 1 | 2001 | 19042 | 0.010 |
Why?
|
| Infliximab | 1 | 2002 | 68 | 0.010 |
Why?
|
| Hematologic Agents | 1 | 2001 | 7 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 146 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2001 | 20 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3177 | 0.010 |
Why?
|
| Systole | 1 | 2001 | 206 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 148 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1992 | 7205 | 0.010 |
Why?
|
| Myocarditis | 1 | 2001 | 137 | 0.010 |
Why?
|
| Organ Size | 1 | 2001 | 467 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 451 | 0.010 |
Why?
|
| Child | 1 | 2000 | 25840 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 676 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 488 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 17517 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 217 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 1999 | 72 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 68 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1998 | 106 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 261 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 271 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 1997 | 3 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1997 | 8 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 449 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1764 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 729 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2001 | 629 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2001 | 804 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 1070 | 0.010 |
Why?
|
| Lipolysis | 1 | 1996 | 83 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1996 | 91 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 826 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1999 | 382 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 1400 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 1598 | 0.010 |
Why?
|
| Fasting | 1 | 1996 | 308 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1736 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 826 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 1492 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1997 | 810 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1814 | 0.010 |
Why?
|
| Quality of Life | 1 | 2002 | 2157 | 0.010 |
Why?
|
| Genotype | 1 | 1997 | 2806 | 0.010 |
Why?
|
| Placebos | 1 | 1991 | 241 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 4806 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 3104 | 0.000 |
Why?
|